SG11201506398SA - Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection - Google Patents

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Info

Publication number
SG11201506398SA
SG11201506398SA SG11201506398SA SG11201506398SA SG11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA SG 11201506398S A SG11201506398S A SG 11201506398SA
Authority
SG
Singapore
Prior art keywords
eimeria
compositions
methods
immune responses
limiting
Prior art date
Application number
SG11201506398SA
Other languages
English (en)
Inventor
John R Barta
Luc Berghman
Lisa Bielke
Billy Hargis
Srichaitanya Shivaramaiah
Olivia B Faulkner
Original Assignee
Univ Arkansas
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Texas A & M Univ Sys filed Critical Univ Arkansas
Publication of SG11201506398SA publication Critical patent/SG11201506398SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201506398SA 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection SG11201506398SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764681P 2013-02-14 2013-02-14
PCT/US2014/016359 WO2014127185A1 (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Publications (1)

Publication Number Publication Date
SG11201506398SA true SG11201506398SA (en) 2015-09-29

Family

ID=51354559

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506398SA SG11201506398SA (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
SG10202109925T SG10202109925TA (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202109925T SG10202109925TA (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Country Status (24)

Country Link
US (6) US9603915B2 (de)
EP (2) EP2956165B1 (de)
JP (2) JP6532407B2 (de)
KR (1) KR102228324B1 (de)
CN (2) CN105142665A (de)
AR (1) AR094791A1 (de)
AU (1) AU2014216246B2 (de)
BR (1) BR112015019283B1 (de)
CA (1) CA2900644C (de)
CL (1) CL2015002273A1 (de)
DK (1) DK2956165T3 (de)
EA (1) EA030929B1 (de)
ES (1) ES2758759T3 (de)
HK (1) HK1218880A1 (de)
HU (1) HUE047484T2 (de)
MX (1) MX2015010555A (de)
MY (1) MY173328A (de)
NZ (1) NZ711019A (de)
PH (1) PH12015501784A1 (de)
PL (1) PL2956165T3 (de)
PT (1) PT2956165T (de)
SG (2) SG11201506398SA (de)
WO (1) WO2014127185A1 (de)
ZA (1) ZA201505638B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3156538C (en) * 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
MX2015010555A (es) 2013-02-14 2015-09-28 Univ Arkansas Composiciones y metodos para mejorar las respuestas inmunes ante una infeccion por eimeria o una infeccion limitante por eimeria.
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
CN104940924B (zh) * 2015-05-29 2018-01-16 中国农业大学 一种球虫佐剂及其应用
AR108688A1 (es) * 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
CN106047914A (zh) * 2016-05-10 2016-10-26 吉林大学 一种用于预防猪弓形虫病的重组卡介苗及制备方法
EP3635108A4 (de) * 2017-06-07 2021-03-31 Spark Therapeutics, Inc. Verstärkungsmittel für verbesserte zelltransfektion und/oder rav-vektor-produktion
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0574466B1 (de) 1991-03-05 1999-05-19 The Wellcome Foundation Limited Expression rekombinanter proteine in attenuierten bakterien
WO1993008207A1 (en) 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
WO1994005326A1 (en) 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
EP0763057B1 (de) 1994-04-28 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
KR19980702490A (ko) 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
KR100453314B1 (ko) 1995-06-07 2004-12-17 임뮤넥스 코포레이션 Cd40l 돌연변이 단백질
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
EP1059932A1 (de) 1997-12-19 2000-12-20 Immunex Corporation Methode zur verminderung der empfindlichkeit gegenüber hiv-infektionen
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
EP1970449B1 (de) 1998-09-04 2010-11-03 Emergent Product Development UK Limited Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger.
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
AU3966200A (en) 1999-04-16 2000-11-02 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (de) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vektoren, die Gene enthalten, die für CD40 und/oder CD40L kodieren die unter der Kontrolle von einer Cytokin-induzierbaren Promotorsequenz sind. Dieser Promotor stammt von einem menschlischen akutphasen-Serumamyloid-A-Gen. Verfahren zur Herstellung derselben und Verwendung davon
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
AU1084901A (en) 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
PT1112747E (pt) 1999-12-28 2004-10-29 Akzo Nobel Nv Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
ES2244617T3 (es) 2000-03-17 2005-12-16 Pharmacia & Upjohn Co Llc Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados.
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
CA2447576C (en) 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents
PT1407004E (pt) 2001-05-15 2009-08-31 Ortho Mcneil Janssen Pharm Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ATE454394T1 (de) 2001-07-06 2010-01-15 Abic Biolog Lab Ltd Rekombinantes, 250 kda grosses antigen aus sporozoiten/merozoiten von eimeria maxima codierende nukleinsäuren und ihre verwendungen
ZA200400479B (en) 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003028441A1 (en) 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
ATE395602T1 (de) 2001-12-19 2008-05-15 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ATE399180T1 (de) 2001-12-21 2008-07-15 Immunex Corp Rekombinante polypeptide
JP4304077B2 (ja) 2002-02-13 2009-07-29 イミュノロジー ラボラトリーズ インコーポレイテッド 微生物感染の処置のための組成物および方法
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
CA2526895A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
AU2003295653B2 (en) 2002-11-20 2007-08-16 The Feinstein Institute Of Medical Research Use of HMGB polypeptides for increasing immune responses
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
EP1768698A4 (de) 2004-06-17 2009-01-28 Medimmune Inc Immunogene zusammensetzungen mit hmgb1-polypeptiden
US20080075728A1 (en) 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
CA2577597A1 (en) * 2004-08-19 2006-02-23 Proteome Systems Intellectual Property Pty Ltd. Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EP1809737B9 (de) 2004-10-07 2011-10-05 Argos Therapeutics, Inc. Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
EP1909834A2 (de) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Verwendung von hmgb1-antagonisten zur behandlung von entzündungskrankheiten
US20100047231A1 (en) 2005-10-07 2010-02-25 Aintzane Zabaleta Azpiroz Immuno-Stimulant Combination for Prophylaxis and Treatment of Hepatitis C
EP1951862B1 (de) 2005-11-07 2013-07-24 MicroVAX, LLC Cd40-ligand-fusionsproteinimpfstoff
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
MY188753A (en) 2006-09-18 2021-12-29 Univ Arkansas Compositions and methods of enhancing immune responses
EP2139913A4 (de) 2007-03-08 2011-09-21 Mayo Foundation Einleitung von immunvermitteltem tumorzelltod
CN101024076B (zh) 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CA3156538C (en) * 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
CN101234196A (zh) 2007-11-30 2008-08-06 吉林大学 球虫重组卡介苗及制备方法
US8450076B2 (en) 2008-09-11 2013-05-28 Institut Pasteur Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
CA2743262C (en) 2008-11-13 2021-11-02 Intervet International B.V. Eimeria vaccine for turkeys
US20100150958A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
JP2011072284A (ja) * 2009-10-01 2011-04-14 Mitsubishi Chemicals Corp 抗体の製造方法及びそれに用いる免疫原性組成物
EA023058B1 (ru) 2010-01-21 2016-04-29 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Вакцинные векторы и способы усиления иммунных ответов
PT2579901T (pt) 2010-06-09 2019-11-05 Univ Arkansas Vacina e métodos para reduzir infeção por campylobacter
PT2911676T (pt) 2012-10-29 2020-08-05 Univ Arkansas Adjuvantes das mucosas e sistemas de administração inovadores
MX2015010555A (es) 2013-02-14 2015-09-28 Univ Arkansas Composiciones y metodos para mejorar las respuestas inmunes ante una infeccion por eimeria o una infeccion limitante por eimeria.
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Also Published As

Publication number Publication date
ES2758759T3 (es) 2020-05-06
PT2956165T (pt) 2019-11-29
EP3610887C0 (de) 2023-11-15
KR102228324B1 (ko) 2021-03-15
MY173328A (en) 2020-01-16
AR094791A1 (es) 2015-08-26
CA2900644C (en) 2023-03-14
AU2014216246B2 (en) 2018-12-20
KR20150119110A (ko) 2015-10-23
BR112015019283A2 (pt) 2017-07-18
JP2019073554A (ja) 2019-05-16
DK2956165T3 (da) 2019-12-02
PH12015501784B1 (en) 2015-12-07
EA030929B1 (ru) 2018-10-31
US11364290B2 (en) 2022-06-21
EP2956165A1 (de) 2015-12-23
JP6532407B2 (ja) 2019-06-19
HUE047484T2 (hu) 2020-04-28
ZA201505638B (en) 2023-05-31
AU2014216246A2 (en) 2015-10-01
US9884099B2 (en) 2018-02-06
US20160000895A1 (en) 2016-01-07
EA201591488A1 (ru) 2016-01-29
US20210008184A1 (en) 2021-01-14
PL2956165T3 (pl) 2020-04-30
JP6874031B2 (ja) 2021-05-19
HK1218880A1 (zh) 2017-03-17
WO2014127185A1 (en) 2014-08-21
US9603915B2 (en) 2017-03-28
US20180169198A1 (en) 2018-06-21
EP3610887A1 (de) 2020-02-19
US20220288175A1 (en) 2022-09-15
EP3610887B8 (de) 2024-01-24
US20170182136A1 (en) 2017-06-29
PH12015501784A1 (en) 2015-12-07
US10792351B2 (en) 2020-10-06
AU2014216246A8 (en) 2015-11-19
US11904005B2 (en) 2024-02-20
AU2014216246A1 (en) 2015-09-10
CL2015002273A1 (es) 2015-12-04
EP2956165B1 (de) 2019-09-11
EP2956165A4 (de) 2016-09-21
BR112015019283B1 (pt) 2023-12-19
EP3610887B1 (de) 2023-11-15
MX2015010555A (es) 2015-09-28
US10328137B2 (en) 2019-06-25
JP2016513956A (ja) 2016-05-19
US20190298815A1 (en) 2019-10-03
CN105142665A (zh) 2015-12-09
CA2900644A1 (en) 2014-08-21
SG10202109925TA (en) 2021-10-28
NZ711019A (en) 2019-07-26
CN111956796A (zh) 2020-11-20

Similar Documents

Publication Publication Date Title
HK1218880A1 (zh) 增强對艾美球蟲的免疫應答或限制艾美球蟲感染的組合物和方法
HK1212729A1 (zh) 核糖核酸調節子組合物和使用方法
HK1207001A1 (en) Immunostimulatory compositions and methods of use thereof
EP2964235A4 (de) Antimikrobielle antibiofilm-zusammensetzungen und verfahren zur verwendung davon
HK1219045A1 (zh) 增强對腸道病原體免疫應答的組合物和方法
GB201320723D0 (en) Composition and methods of treatment
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HK1210187A1 (en) Compositions and methods related to prevention and treatment of rabies infection
EP2968244A4 (de) Zusammensetzungen und verfahren zur verwendung von aligalverbindungen
HK1221641A1 (zh) 疫苗組合物及使用方法
EP2897639A4 (de) Verbesserte impfstoffzusammensetzungen und verfahren zur verwendung
HK1209031A1 (en) Polysaccharide compositions and methods of use
HK1254514A1 (zh) 用於增强疫苗接種免疫反應的方法及組合物
HK1217715A1 (zh) 治療中風的組合物及方法
IL244537A0 (en) New administration preparations and methods of their use
HK1203979A1 (en) Compositions and methods of modulating an immune response
EP2931040A4 (de) Verfahren und zusammensetzungen zur behandlung von hiv-infektionen
IL243331A0 (en) Methods and compositions of granular formulations
EP2841164A4 (de) Für die haut geeignete zusammensetzungen und verwendungsverfahren
GB201314498D0 (en) Improvements to Receivers and Method of Use Thereof